Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism

A man smiling in a research lab.
September 7, 2021
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.

Williams Talks to KXAN About How Thin Film Freezing Can Help Treat COVID Patients

A man wearing glasses.
July 30, 2021
Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Fight Against Antibiotic-Resistant Bacteria Has a Glowing New Weapon

A 3D representation of the chemical probe as it bridges two zinc molecules
June 2, 2021
Chemistry Assistant Professor Emily Que, Ph.D. and the College of Pharmacy’s Walt Fast, Ph.D. are working together to research new methods to fight against antibiotic resistance. The fluorescent chemical probe developed by Que and Fast may help find a different way to combat resistant bacteria.

Williams Wants to Turn COVID-19 Vaccine into Powder to Help with Storage and Distribution

A powder in a vial.
November 25, 2020
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.

Live Subject Testing Shows Promising Delivery Method for COVID-19 Antiviral Treatment

A microscopic image.
September 23, 2020
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.

Mukhopadhyay Wins Research Excellence Award

A man standing in a research laboratory.
September 10, 2020
Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.

Richburg Receives NIH Grant Award for Toxicant Injury Research

A man smiling
August 10, 2020
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.

New Delivery Method Could Make Niclosamide an Effective Antiviral to Treat COVID-19

Two men in suits smiling.
April 6, 2020
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.